IXHL Stock Summary and Trading Ideas (Incannex Healthcare | NASDAQ:IXHL)

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Incannex Healthcare trades on the NASDAQ stock market under the symbol IXHL.

As of April 23, 2026, IXHL stock price declined to $3.86 with 234,006 million shares trading.

IXHL has a beta of 3.90, meaning it tends to be more sensitive to market movements. IXHL has a correlation of 0.05 to the broad based SPY ETF.

IXHL has a market cap of $53.94 million. This is considered a Micro Cap stock.

Last quarter Incannex Healthcare reported $0 in Revenue and -$.60 earnings per share. This fell short of revenue expectation by $-80,000 and exceeded earnings estimates by $.30.

In the last 3 years, IXHL traded as high as $380.40 and as low as $2.40.

IXHL has underperformed the market in the last year with a return of -77.1%, while the SPY ETF gained +36.2%. In the last 3 month period, IXHL fell short of the market, returning -64.1%, while SPY returned +3.4%. However, in the most recent 2 weeks IXHL has outperformed the stock market by returning +41.9%, while SPY returned +5.1%.

IXHL support price is $3.77 and resistance is $4.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IXHL shares will trade within this expected range on the day.